Yes, the DSMB should know which patients are on placebo vs. RVX-208 in order to determine if the MACE events as well as any adverse events, safety concerns or deaths from non-cardiovascular causes is just common to the entire patient population or specific to placebo or RVX-208. Plus, the DSMB will definitely need to be unblinded for the futility analysis, the purpose of which is to compare the two groups. 

BearDownAZ